• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by SNDL Inc.

    4/30/25 7:55:52 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SNDL alert in real time by email
    6-K 1 sndl-6-k-2025_q1.htm 6-K 6-K

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

    SECURITIES EXCHANGE ACT OF 1934

    For the month of April 2025

    Commission File Number 001-39005

    SNDL INC.

    (Registrant’s name)

    #101, 17220 Stony Plain Road NW

    Edmonton, AB T5S 1K6

    Tel.: (780) 944-9994

    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

    Form 20-F ☐ Form 40-F ☒

     

     

     


    INCORPORATION BY REFERENCE

    This report on Form 6-K shall be deemed to be incorporated by reference in SNDL Inc.’s registration statements on Form S-8 (File No. 333-233156, File No. 333-262233, File No. 333-267510, File No. 333-269242, File No. 333-278683 and File No. 333-286169) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    SNDL INC.

    Date: April 30, 2025

    By:

    /s/ Alberto Paredero Quiros

     

    Name:

    Alberto Paredero Quiros

     

    Title:

    Chief Financial Officer

     

    EXHIBIT

     

    Exhibit

     

    Description of Exhibit

    99.1

     

    Condensed Consolidated Interim Financial Statements for the Three Months Ended March 31, 2025

    99.2

     

    Management’s Discussion and Analysis for the Three Months Ended March 31, 2025

    99.3

     

    Form 52-109F2 Certificate of Interim Filings by CEO (pursuant to Canadian regulations)

    99.4

     

    Form 52-109F2 Certificate of Interim Filings by CFO (pursuant to Canadian regulations)

     

     


    Get the next $SNDL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNDL

    DatePrice TargetRatingAnalyst
    7/17/2024Speculative Buy
    Canaccord Genuity
    8/16/2022$5.00Hold → Speculative Buy
    Canaccord Genuity
    5/3/2022$0.60 → $0.70Underperform → Market Perform
    BMO Capital Markets
    More analyst ratings